Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of S241656 (BDTX-4933) in RAS/MAPK mutation-positive solid tumors
jRCT2031250784Phase 2Recruiting
- Sponsor
- Servier
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of bdtx-4933 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC) and 2 more (13 arms), sponsored by Servier. Primary endpoints: Incidence of dose-limiting toxicities, Number of adverse events and serious adverse events and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
bdtx-4933
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)colorectal adenocarcinomabiliary cancer
Beyond the preview
Go deeper on jRCT2031250784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250784.